Ahn A, Park S-S, Kim Y, Lee JY, Lee J-M, Jung J, Kim M, Min C-K. Minimal residual disease assessment in transplanteligible patients with multiple myeloma: real-world applications of multiparametric flow cytometry- DURAClone (CAREMM-2104). haematol [Internet]. 2020Sep.10 [cited 2024Nov.28];. Available from: https://haematologica.org/article/view/haematol.2024.285278